文献速递妇科生殖医学

194个国家多囊卵巢综合征全球疾病负担:2017年全球疾病负担研究

Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.
PubMed 文献 · Hum Reprod · 2021-01-01

基于GBD 2017数据,对194个国家和地区的育龄女性(15-49岁)多囊卵巢综合征(PCOS)发病率和伤残调整寿命年(DALYs)进行年龄和SDI分层分析。全球年龄标化发病率2017年升至82.44/10万,2007-2017年增长1.45%;年龄标化DALYs率升至21.96/10万,增长1.91%。中SDI和中高SDI地区增幅最大。

要点

  • 2017年年龄标化发病率和DALYs率分别为82.44/10万和21.96/10万。
  • 2007-2017年年龄标化发病率和DALYs率分别增长1.45%和1.91%。

核心结论

  • 全球育龄女性PCOS年龄标化发病率和DALYs率从2007年到2017年略有增加,多数地区和国家呈相同趋势。

研究设计与样本

  • 基于GBD 2017数据的系统分析,按年龄和SDI分层,覆盖194个国家和地区的育龄女性(15-49岁)。

主要发现

  • 全球育龄女性PCOS发病例数为1.55百万(95% UI:1.19-2.08),相关DALYs为0.43百万(0.19-0.82)。
  • 2017年全球年龄标化发病率为82.44/10万(64.65-100.24),2007-2017年增长1.45%(1.43-1.47%)。
  • 2017年全球年龄标化DALYs率为21.96/10万(12.78-31.15),2007-2017年增长1.91%(1.89-1.93%)。
  • 年龄标化发病率和DALYs率增幅最大的地区分别为中SDI地区和中高SDI地区。
  • 2017年年龄标化发病率和DALYs率最高的地区为安第斯拉丁美洲;2007-2017年增幅最大的地区为热带拉丁美洲。

关键数值与推荐

  • 全球年龄标化发病率82.44/10万(95% UI:64.65-100.24),年龄标化DALYs率21.96/10万(12.78-31.15)。
  • 2007-2017年年龄标化发病率增长1.45%(1.43-1.47%),DALYs率增长1.91%(1.89-1.93%)。

临床怎么用

  • 了解PCOS负担的地域差异有助于资源分配和制定有效的预防策略。

局限性

  • 部分区域数据有限可能导致估计的不确定性区间较宽。
  • PCOS表型复杂且诊断标准不断变化,发病率可能被低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the current burden of polycystic ovary syndrome (PCOS) at the global, regional, and country-specific levels in 194 countries and territories according to age and socio-demographic index (SDI)? SUMMARY ANSWER: Slight increases in age-standardized incidence of PCOS and associated disability-adjusted life-years (DALYs) were evidenced among women of reproductive age (15-49 years) from 2007 to 2017 at the global level, and in most regions and countries. WHAT IS KNOWN ALREADY: No detailed quantitative estimates of the PCOS incidence and DALYs by age and SDI in these 194 countries and territories have been published previously. STUDY DESIGN, SIZE, DURATION: An age- and SDI-stratified systematic analysis of the PCOS incidence and DALYs across 194 countries and territories has been performed. PARTICIPANTS/MATERIALS, SETTING, METHODS: We used data from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2017 to estimate the total and age-standard PCOS incidence rates and DALYs rates among women of reproductive age in both 2007 and 2017, and the trends in these parameters from 2007 to 2017. MAIN RESULTS AND THE ROLE OF CHANCE: Globally, women of reproductive age accounted for 1.55 million (95% uncertainty intervals (UIs): 1.19-2.08) incident cases of PCOS and 0.43 million (0.19-0.82) associated DALYs. The global age-standardized PCOS incidence rate among women of reproductive age increased to 82.44 (64.65-100.24) per 100 000 population in 2017, representing an increase of 1.45% (1.43-1.47%) from 2007 to 2017. The rate of age-standardized DALYs increased to 21.96 (12.78-31.15) per 100 000 population in 2017, representing an increase of 1.91% (1.89-1.93%) from 2007 to 2017. Over the study period, the greatest increase in the age-standardized PCOS incidence and DALYs rates were observed in the middle-SDI and high-middle SDI regions, respectively. At the GBD regional level, the highest age-standardized incidence and DALY rates in 2017 were observed in Andean Latin America, whereas the largest percentage increases in both rates from 2007 to 2017 were observed in Tropical Latin America. At the national level, Ecuador, Peru, Bolivia, Japan, and Bermuda had the highest age-standardized incidence rates and DALYs rates in both 2007 and 2017. The highest increases in both the age-standardized incidence rates and DALYs rates from 2007 to 2017 were observed in Ethiopia, Brazil, and China. LIMITATIONS, REASONS FOR CAUTION: Although the GBD (2017) study aimed to gather all published and unpublished data, the limited availability of data in some regions might have led to the estimation of wide UIs. Additionally, the PCOS phenotype is complicated and the diagnostic criteria are constantly changing. Consequently, the incidence of PCOS might have been underestimated. WIDER IMPLICATIONS OF THE FINDINGS: Knowledge about the differences in the PCOS burden across various locations will be valuable for the allocation of resources and formulation of effective preventive strategies. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by grants from the Innovative Talent Support Plan of the Medical and Health Technology Project in Zhejiang Province (2021422878), Ningbo Science and Technology Project (202002N3152), Ningbo Health Branding Subject Fund (PPXK2018-02), Sanming Project of Medicine in Shen-zhen (SZSM201803080), and National Social Science Foundation (19AZD013). No potential conflicts of interest relevant to this article were reported. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod. 2021. PMID: 33501984. doi:10.1093/humrep/deaa371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。